ISRG Intuitive Surgical (NASDAQ) pre-market +1.55% 18 Feb 2026: analysts’ targets

ISRG stock opened pre-market at $493.35 on 18 Feb 2026, up 1.55% as traders digest recent earnings and analyst moves. Intuitive Surgical, Inc. (NASDAQ: ISRG) reported a strong January quarter with $2.53 EPS and $2.87 billion revenue, beating consensus. The company’s digital surgery and AI-enabled diagnostic workstreams keep ISRG in the AI stocks conversation, and Meyka AI provides this data-driven update for U.S. market investors.

ISRG stock: recent earnings and growth drivers

Intuitive Surgical beat estimates on 22 Jan 2026, reporting $2.53 EPS and $2.87 billion revenue. Revenue rose 18.80% year-over-year, showing ongoing demand for da Vinci systems and instruments.

The company also highlighted growth in diagnostics with the Ion system and recurring instruments and services revenue. That mix supports margin expansion and a net margin of 28.38% for the quarter.

ISRG stock: valuation and key financial metrics

ISRG trades at PE 62.69 and has EPS of 7.87 on a trailing basis. Market capitalization stands at $175.20 billion and shares outstanding are 355,130,237.

Balance-sheet metrics are strong: cash per share $16.72, current ratio 4.87, and debt to equity 0.02. High multiples reflect durable margins but also raise valuation risk versus peers.

ISRG stock: technicals and trading context

Price sits at $493.35, below the 50-day average $542.29 and 200-day average $515.97, with a 52-week range of $425.00–$609.08. Daily volume is 1,583,207 versus avg 1,919,676.

Momentum indicators show an RSI of 65.69 and a MACD histogram of 0.11, suggesting positive but not extreme short-term strength for pre-market trading.

ISRG stock: analyst consensus and price targets

Wall Street consensus remains constructive with a MarketBeat average target of $617.23 and a mix of Buy and Hold ratings. Recent targets range from $550.00 to $750.00 by firm analysts.

Analyst action has driven intramarket debate; UBS and Goldman Sachs provide differing stances, which keeps near-term price discovery active for investors.

ISRG stock: Meyka grade and model forecast

Meyka AI rates ISRG with a score out of 100: 79.60 (B+), Suggestion: BUY. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a yearly price of $604.32, implying +22.50% from the current $493.35. Forecasts are model-based projections and not guarantees.

ISRG stock: risks and opportunities for AI-focused investors

Opportunity: expanding digital tools and diagnostics can increase recurring software and services revenue and improve lifetime value per system. Management cited adoption gains in advanced procedures.

Risk: rich valuation with PE above 60 and insider selling activity. Institutional ownership near 83.64% concentrates flows and can amplify price moves.

Final Thoughts

Key takeaways for ISRG stock on 18 Feb 2026: the company delivered a clear beat in the latest quarter, with $2.53 EPS and $2.87 billion revenue, and continues to push AI-enabled surgical and diagnostic offerings. Valuation remains rich at a PE of 62.69, which leaves upside tied to above-consensus growth and margin expansion. Meyka AI’s model projects a yearly target of $604.32, an implied +22.50% upside from the current $493.35. Analyst targets average $617.23, reflecting a broad range of views from $550.00 to $750.00. Volume and technicals show cautious momentum, and insider sales add a watchpoint. Use these data points to weigh ISRG’s growth profile against its premium valuation. For live updates and deeper screens, see our ISRG page at https://meyka.ai/stocks/ISRG and coverage from MarketBeat and Barron’s for the latest analyst notes and filings

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.